Showing results (141-150 of 242) with videos related to

Sort By:
Pageof 25
The Journal of Urology|November 16, 2004
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 yearsManfred P Wirth, William A See, David G McLeod, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 11, 2017
Quantification of MicroRNAs in Urine-Derived SpecimensSusanne Fuessel, Andrea Lohse-Fischer, Dana Vu Van, et al.
Annals of Surgical Oncology|February 23, 2018
Urinary Diversion After Radical Cystectomy for Bladder Cancer: Comparing Trends in the US and Germany from 2006 to 2014Christer Groeben, Rainer Koch, Martin Baunacke, et al.
Der Urologe. Ausg. A|August 2, 2021
[On the practice of therapy decision in locally limited prostate cancer: surgery vs. radiation-who benefits? : Allocation and results of a monocentric, cumulative long-term study]W -D U Böhm, R Koch, S Latarius, et al.
BJU International|October 13, 2004
Induction of proliferation and differentiation of cultured urothelial cells on acellular biomaterialsGouya Ram-Liebig, Axel Meye, Oliver W Hakenberg, et al.
Cancer Letters|April 15, 2003
Tissue specific expression and serum levels of human tissue factor in patients with urological cancerYvonne Förster, Axel Meye, Sybille Albrecht, et al.
Urologia Internationalis|March 20, 2014
Primary tumor size in renal cell cancer in relation to the occurrence of synchronous metastatic diseaseStefan Zastrow, Anh Phuong, Immanuel von Bar, et al.
The Journal of Urology|November 16, 2004
Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatmentKai Kraemer, Susanne Fuessel, Matthias Kotzsch, et al.
BJU International|January 25, 2006
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerDavid G McLeod, Peter Iversen, William A See, et al.
Nanotechnology|September 17, 2014
Chemosensitizing effects of carbon-based nanomaterials in cancer cells: enhanced apoptosis and inhibition of proliferation as underlying mechanismsKati Erdmann, Jessica Ringel, Silke Hampel, et al.
Pageof 25